UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 0.5% in the third quarter, HoldingsChannel.com reports. The firm owned 177,756 shares of the biopharmaceutical company’s stock after buying an additional 947 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Ultragenyx Pharmaceutical were worth $9,874,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of RARE. Millennium Management LLC grew its stake in Ultragenyx Pharmaceutical by 103.8% during the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock worth $76,065,000 after buying an additional 942,529 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $17,468,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Ultragenyx Pharmaceutical by 63.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 830,375 shares of the biopharmaceutical company’s stock valued at $34,128,000 after acquiring an additional 323,280 shares during the period. First Light Asset Management LLC raised its position in Ultragenyx Pharmaceutical by 21.8% in the 2nd quarter. First Light Asset Management LLC now owns 963,146 shares of the biopharmaceutical company’s stock valued at $39,585,000 after purchasing an additional 172,700 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Ultragenyx Pharmaceutical by 46.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 542,373 shares of the biopharmaceutical company’s stock worth $30,129,000 after purchasing an additional 172,126 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on RARE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. HC Wainwright boosted their target price on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. cut their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.46.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $49.38 on Monday. The company has a market cap of $4.56 billion, a price-to-earnings ratio of -7.63 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37. The business’s fifty day moving average is $51.17 and its two-hundred day moving average is $48.93.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm’s revenue was up 42.3% on a year-over-year basis. During the same period in the prior year, the company earned ($2.23) EPS. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This trade represents a 7.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.